The FDA and the Federal Trade Commission have posted joint warning letters to companies that make and distribute opioid cessation products.
The two watchdogs warned that the companies are illegally marketing their unapproved products as treatments or even cures for people with opioid addiction and withdrawal. Selling unapproved products as therapies for opioid addiction is a violation of the Federal Food, Drug and Cosmetic Act and also violates the Federal Trade Commission Act, according to the FDA and FTC.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.